ATMA Journey Centers Inc. is pleased to announce it has submitted an N500 3,4-Methylenedioxymethamphetamine (MDMA) phase II Clinical Trial Application (CTA) to Health Canada.
ATMA Journey Centers Inc. is pleased to announce it has submitted an N500 3,4-Methylenedioxymethamphetamine (MDMA) phase II Clinical Trial Application (CTA) to Health Canada.